Novo Nordisk's U.S.-listed shares slipped roughly 2% on Thursday after Deutsche Bank downgraded the Danish pharmaceutical giant to Sell from Hold, trimming its price target to 265 Danish kroner from 290 kroner. The move reflects mounting concerns about the company's ability to sustain growth amid intensifying competition in the obesity-drug market and recent clinical trial disappointments.
Deutsche Bank flags growth concerns
Analyst Emmanuel Papadakis cited the failure of Novo Nordisk's Ziltivekimab trial, which did not reduce the risk of heart attack or stroke in a late-stage cardiovascular study. That setback led the bank to remove the drug from its future revenue projections and cut mid-term estimates. Papadakis also expressed skepticism about the potential sales boost from expanded Medicare coverage of weight-loss drugs in the U.S., noting that any increase would likely be limited.
The analyst highlighted uncertainty over whether Novo Nordisk can return to meaningful growth by 2027, and pointed to patent expirations further down the road as an additional challenge. The downgrade comes after a turbulent period for the company, whose shares have fallen about 70% from their June 2024 peak, pressured by competition from Eli Lilly and the growing availability of lower-cost or knockoff versions of its Ozempic and Wegovy products.
Competition and pricing pressure weigh on Novo
Novo Nordisk has been working to diversify its portfolio beyond its established diabetes and obesity franchises, aiming to expand into treatments for related conditions. However, recent pipeline developments have raised questions about how quickly those efforts can generate new sources of growth. The company has also faced pricing pressure, particularly in the U.S., where a deal under the Trump administration to lower drug prices in exchange for broader coverage of weight-loss medicines through federal health programs has added to concerns about future pricing power.
Competition in the GLP-1 market remains a major issue. Eli Lilly has continued to strengthen its position, with its oral weight-loss treatment receiving its first European regulatory approval in August. That puts additional pressure on Novo Nordisk's Wegovy franchise as both companies expand their oral obesity-drug offerings. Novo Nordisk shares remain below their 52-week high of 410 Danish kroner, although they have recovered from a 52-week low of 224.3 kroner.
Wegovy pill expansion and investor update ahead
On Thursday, Novo Nordisk announced that Chinese regulators had accepted its application to market the Wegovy weight-loss pill in the country. The pill has already received regulatory approvals in the U.S., UK, European Union, United Arab Emirates, and Bahrain. The company is also preparing for a key investor update next month, which JP Morgan expects to include an overview of Novo Nordisk's pipeline, including next-generation obesity and diabetes treatments, as well as broader strategic plans.
The upcoming investor event could provide investors with more detail on how Novo Nordisk plans to address its competitive challenges and rebuild growth following recent pipeline setbacks. As the company navigates these headwinds, its ability to execute on its pipeline and pricing strategy will be closely watched. For more on how other companies are handling market pressures, see HP's recent slide and Alphabet's dip. Additionally, Intuit's soft forecast and Nio's support break highlight broader market volatility.
This article is for informational purposes only and does not constitute financial advice.
